Allan Coukell is Pew’s senior director for health programs. He oversees initiatives related to drug and medical device innovation and safety, medical conflicts-of-interest, the pharmaceutical supply chain, pharmacy compounding, antibiotic resistance, prescription drug abuse, FDA, specialty drugs, food safety, school nutrition, as well as other efforts related to health costs and care delivery.
Prior to joining Pew, he practiced as a clinical pharmacist in oncology at the London Health Sciences Center and Ontario Regional Cancer Center, served as a senior medical writer and editor with the medical journal publisher Adis International, and covered health and science as a reporter and producer for WBUR (NPR) in Boston and Radio New Zealand. He is Vice Chair of the Medical Device Innovation Consortium and a board member of the Reagan Udall Foundation for the FDA. He served previously as consumer representative on the FDA’s Cardiovascular and Renal Drugs Advisory Committee.
The House passed the Opioid Use Disorder Treatment Expansion and Modernization Act, sponsored by Representatives Larry Bucshon (R-IN) and Paul Tonko (D-NY). This legislation includes a provision that would allow nurse practitioners and physician assistants to prescribe buprenorphine, a drug used to relieve withdrawal symptoms and cravings for opioids. Read More
Opioid misuse is a U.S. public health crisis that does not discriminate based on gender. National Women’s Health Week (May 8-14) is a good time to spotlight just how women are being affected by the inappropriate use of prescription drugs—and what can be done to stop it. Read More
On April 15, The Pew Charitable Trusts sent a letter to Senators Roy Blunt (R-MO) and Patty Murray (D-WA), and to Representatives Tom Cole (R-OK) and Rosa DeLauro (D-CT), urging them to include funding for the prevention and treatment of opioid use disorders in their committees’ fiscal year 2017 Labor, Health and Human Services, Education, and Related Agencies appropriations bills. Read More